Long-term Responders to Nivolumab in Previously Treated Advanced Renal Cell Carcinoma: a Sub-Analysis of Meet-URO15 Study
Carlo Messina,Martina Catalano,Giandomenico Roviello,Annalice Gandini,Marco Maruzzo,Ugo De Giorgi,Paolo Pedrazzoli,Andrea Sbrana, Paolo Andrea Zucal,Cristina Masini,Emanuele Naglieri,Giuseppe Procopio,Michele Milella,Fabio Catalano,Lucia Fratino,Stefania Pipitone,Riccardo Ricotta,Stefano Panni,Veronica Mollica,Mariella Soraru,Veronica Prati,Francesco Atzori,Marilena Di Napoli,Marco Messina,Franco Morelli,Giuseppe Prati,Franco Nole,Andrea Malgeri,Marianna Tudini,Francesca Vignani,Alessia Cavo,Alessio Signori,Giuseppe Luigi Banna,Pasquale Rescigno,Sebastiano Buti,Sara Elena Rebuzzi,Giuseppe Fornarini CANCER IMMUNOLOGY IMMUNOTHERAPY（2024）
Key words
Metastatic renal cell carcinoma,Nivolumab,Immunotherapy,Long-term response,Prognostic factors
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper